Bokf Na Boosts Stake in Bristol Myers Squibb Company $BMY

Key Points

• Bokf Na raised its stake in Bristol Myers Squibb by 45.8% in Q3 to 264,580 shares (an additional 83,079), worth about $11.93 million.
• BMY reported Q results with an EPS of $1.26 (missing the $1.65 estimate) but revenue of $12.50 billion (beating estimates), set FY2026 guidance of $6.05–$6.35 EPS, and holds a MarketBeat consensus rating of "Hold" with an average price target of $61.00.
• The company declared a quarterly dividend of $0.63 per share (annualized $2.52), a yield of roughly 4.3%, and about 76.41% of the stock is owned by institutional investors.

Bokf Na raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 45.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 264,580 shares of the biopharmaceutical company's stock after acquiring an additional 83,079 shares during the period. Bokf Na's holdings in Bristol Myers Squibb were worth $11,933,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of BMY. Kendall Capital Management raised its holdings in shares of Bristol Myers Squibb by 6.7% during the 3rd quarter. Kendall Capital Management now owns 59,482 shares of the biopharmaceutical company's stock worth $2,683,000 after acquiring an additional 3,730 shares during the period. Mackenzie Financial Corp grew its holdings in shares of Bristol Myers Squibb by 13.6% in the third quarter. Mackenzie Financial Corp now owns 1,254,471 shares of the biopharmaceutical company's stock valued at $56,577,000 after purchasing an additional 149,701 shares during the period. Franklin Resources Inc. increased its position in Bristol Myers Squibb by 3.1% during the third quarter. Franklin Resources Inc. now owns 8,702,170 shares of the biopharmaceutical company's stock worth $392,468,000 after purchasing an additional 265,359 shares during the last quarter. Van ECK Associates Corp raised its stake in Bristol Myers Squibb by 67.8% during the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company's stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the period. Finally, FourThought Financial Partners LLC raised its stake in Bristol Myers Squibb by 3.0% during the third quarter. FourThought Financial Partners LLC now owns 9,615 shares of the biopharmaceutical company's stock worth $434,000 after purchasing an additional 284 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BMY. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 13th. Citigroup boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "neutral" rating in a research note on Friday, February 6th. Scotiabank restated a "sector perform" rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of "Hold" and an average price target of $61.00.

Bristol Myers Squibb Stock Down 1.8%

BMY opened at $58.93 on Friday. The stock has a market capitalization of $120.00 billion, a P/E ratio of 17.08, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The business's 50-day simple moving average is $58.12 and its 200-day simple moving average is $51.32.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the firm earned $1.67 EPS. The company's quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.